对“生命最后一年维生素K拮抗剂治疗质量”的更正

IF 14.6 2区医学 Q1 HEMATOLOGY

HemaSphere Pub Date : 2025-07-28 DOI:10.1002/hem3.70173

引用次数: 0

摘要

张建军，李建军，张建军，等。生命最后一年维生素K拮抗剂治疗的质量。HemaSphere。2025; 9 (5): e70135。https://doi.org/10.1002/hem3.70135.In手稿的作者列表，一个作者的名字被错误地列为Jamilla Goedgebuur。正确的名字是Jamilla Goedegebuur。原文已被更正。我们为这个错误道歉。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Correction to “Quality of vitamin K antagonist treatment during the last year of life”

Visser C, Kempers EK, Goedegebuur J, et al. Quality of vitamin K antagonist treatment during the last year of life. HemaSphere. 2025;9(5):e70135. https://doi.org/10.1002/hem3.70135.

In the author listing of the manuscript, the name of an author was incorrectly listed as Jamilla Goedgebuur. The correct name is Jamilla Goedegebuur.

The original publication has been corrected. We apologize for this error.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

HemaSphere Medicine-Hematology

CiteScore

6.10

自引率

4.50%

发文量

2776

审稿时长

7 weeks

期刊介绍： HemaSphere, as a publication, is dedicated to disseminating the outcomes of profoundly pertinent basic, translational, and clinical research endeavors within the field of hematology. The journal actively seeks robust studies that unveil novel discoveries with significant ramifications for hematology. In addition to original research, HemaSphere features review articles and guideline articles that furnish lucid synopses and discussions of emerging developments, along with recommendations for patient care. Positioned as the foremost resource in hematology, HemaSphere augments its offerings with specialized sections like HemaTopics and HemaPolicy. These segments engender insightful dialogues covering a spectrum of hematology-related topics, including digestible summaries of pivotal articles, updates on new therapies, deliberations on European policy matters, and other noteworthy news items within the field. Steering the course of HemaSphere are Editor in Chief Jan Cools and Deputy Editor in Chief Claire Harrison, alongside the guidance of an esteemed Editorial Board comprising international luminaries in both research and clinical realms, each representing diverse areas of hematologic expertise.